BLUEPRINT MEDICINES CORPORATION
BPMC US09627Y1091
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2% | -60% | 113% | -4% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Carter Percy H. SR OFF |
128.25 USD |
1,051 Sold |
134,791 USD |
03/07/2025 | 03/07/2025 |
| Rossi Christina COO |
128.25 USD |
1,172 Sold |
150,309 USD |
03/07/2025 | 03/07/2025 |
| Carter Percy H. SR OFF |
127.88 USD |
241 Sold |
30,819 USD |
03/06/2025 | 03/06/2025 |
| Carter Percy H. SR OFF |
127.88 USD |
2,418 Sold |
309,214 USD |
03/06/2025 | 03/06/2025 |
| Albers Jeffrey W. O |
101.02 USD |
4,350 Sold |
439,437 USD |
27/05/2025 | 27/05/2025 |
| Albers Jeffrey W. O |
101.93 USD |
650 Sold |
66,255 USD |
27/05/2025 | 27/05/2025 |
| Rossi Christina COO |
101.72 USD |
57 Sold |
5,798 USD |
19/05/2025 | 19/05/2025 |
| Rossi Christina COO |
100.14 USD |
804 Sold |
80,513 USD |
19/05/2025 | 19/05/2025 |
| Rossi Christina COO |
100.67 USD |
1,413 Sold |
142,247 USD |
19/05/2025 | 19/05/2025 |
| Rossi Christina COO |
100.97 USD |
607 Sold |
61,289 USD |
05/05/2025 | 05/05/2025 |